Author： Davignon Jean-Luc
Publisher： Oxford University Press
ISSN： 1460-2172
Source： British Journal of Rheumatology , Vol.52, Iss.4, 2013-04, pp. : 590-598
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Biotherapies have revolutionized the treatment of RA. However, much work is needed to understand all the mechanisms of these biotherapies, and alternatives are needed to circumvent adverse effects and the high cost of these long-lasting treatments. In this article we outline some of the approaches we have used to target monocytes/macrophages as major components of inflammation and bone homeostasis. We also discuss how anti-TNF- antibodies target monocytes/macrophages in the complex mechanisms contributing to inhibition of inflammation.
Related content
Treatment of early rheumatoid arthritis
By Raza Karim Salmon Mike Buckley Christopher D
Therapy, Vol. 2, Iss. 4, 2005-07 ,pp. :
Access to resources
Recommend
Certolizumab pegol for the treatment of rheumatoid arthritis
By Modesto I Spinello M Nicchi F Cottone M
Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. :
Subcutaneous abatacept for the treatment of rheumatoid arthritis
British Journal of Rheumatology , Vol. 52, Iss. 6, 2013-06 ,pp. :
Etanercept and methotrexate for the treatment of rheumatoid arthritis
Therapy, Vol. 3, Iss. 3, 2006-05 ,pp. :
Treatment of Elderly‐Onset Rheumatoid Arthritis
JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 39, Iss. 10, 1991-10 ,pp. :